Marimed (MRMD) Short term Debt (2013 - 2023)

Marimed (MRMD) posted quarterly Short term Debt of $3.6 million for Q3 2023, little changed quarter-over-quarter from $3.6 million in Q2 2023.

Marimed (MRMD) Short term Debt (2013 - 2023) Analysis & Trends

Marimed (MRMD) has reported Short term Debt for 9 consecutive years, with $3.6 million the latest figure, recorded in Q3 2023.

In Q3 2023, Short term Debt changed N/A year-over-year to $3.6 million; the TTM figure through Sep 2023 stood at $3.6 million (changed N/A YoY), while the FY2020 annual figure was $1.2 million, down 20.41% from the prior year.
Short term Debt steadied at $3.6 million in Q3 2023 per MRMD's latest filing, from $3.6 million in the prior quarter.
Across five years, Short term Debt topped out at $3.6 million in Q2 2023 and bottomed at $77157.0 in Q2 2019.
Historically, Short term Debt has averaged $1.6 million across 3 years, with a median of $1.2 million in 2020.
Annual changes were most pronounced in 2019 — Short term Debt slumped 62.36% — and 2020, when it soared 1703.22%.
Marimed's Short term Debt stood at $1.5 million in 2019, then dropped by 20.41% to $1.2 million in 2020, then surged by 210.93% to $3.6 million in 2023.
Business Quant data shows MRMD's Short term Debt at $3.6 million in Q3 2023, $3.6 million in Q2 2023, and $3.3 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-
10	Marimed	27.77 Mn	19.33 Mn	16.23 Mn

Download Data